Allarity Therapeutics, Inc. (ALLR)
- Previous Close
1.0700 - Open
1.1000 - Bid 0.8424 x 200
- Ask 1.2000 x 400
- Day's Range
1.0800 - 1.1900 - 52 Week Range
0.6140 - 103.8000 - Volume
903,043 - Avg. Volume
2,186,335 - Market Cap (intraday)
18.694M - Beta (5Y Monthly) -0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-15.6500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
www.allarity.comRecent News: ALLR
View More
Performance Overview: ALLR
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALLR
View MoreValuation Measures
Market Cap
18.21M
Enterprise Value
22.77k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.52%
Return on Equity (ttm)
-541.17%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.15M
Diluted EPS (ttm)
-15.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
19.61M
Total Debt/Equity (mrq)
11.43%
Levered Free Cash Flow (ttm)
-15.62M